Company news
Geron Corporation (NASDAQ:GERN) news
Every Geron Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 5, 2026
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
July 22, 2026
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
July 13, 2026
Geron Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
June 19, 2026
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 1, 2026
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
May 12, 2026
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 6, 2026
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
April 22, 2026
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary
April 13, 2026
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 6, 2026
Geron Announces Appointment of New Members to its Board of Directors
March 26, 2026
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
February 25, 2026
Geron Plans to Present at Upcoming Investor Conferences
February 23, 2026
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
February 11, 2026
Geron Corporation Provides 2026 Financial Guidance
January 12, 2026
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 18, 2025
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
December 11, 2025
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit ...
December 8, 2025
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 5, 2025
Geron Corporation to Present at Upcoming Investor Conferences
November 4, 2025
Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid He...
November 3, 2025
Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025
October 27, 2025
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
October 22, 2025
Geron Corporation Announces Executive Leadership Transitions and Appointments
October 13, 2025
Geron to Participate in the 2025 Wells Fargo Healthcare Conference
August 27, 2025
SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors
August 19, 2025
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 8, 2025
Geron Appoints Harout Semerjian as President and Chief Executive Officer
August 6, 2025
Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 6, 2025
Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025
July 28, 2025
Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and ...
May 28, 2025
Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 7, 2025
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2025
Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025
March 31, 2025
Geron Corporation Announces Departure of Chief Executive Officer
March 11, 2025
Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults ...
March 11, 2025
Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
February 26, 2025
Geron to Participate at Upcoming Investor Conferences in March 2025
February 21, 2025
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
February 3, 2025
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower...
December 13, 2024
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combin...
December 10, 2024
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS...
December 10, 2024
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
November 27, 2024
Geron to Participate in the Stifel 2024 Healthcare Conference
November 11, 2024
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
November 11, 2024
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 7, 2024
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
November 7, 2024
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hem...
November 5, 2024
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
October 15, 2024
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
September 9, 2024